AMPAC Fine Chemicals LLC (AFC) announced the acquisition of the UniTao Pharmaceuticals LLC assets, comprising the former Boehringer Ingelheim manufacturing facility in Petersburg, Virginia. 

Dr. Aslam Malik, AFC’s President & CEO, reports, “This is a world-class active pharmaceutical ingredient (API) manufacturing facility with a long history of producing Controlled Substances and Highly Potent APIs. It is a perfect fit for AFC’s growing demand for APIs.”

Dr. Malik adds, “We have also retained a core team of experienced professionals at the Petersburg facility to support cGMP production of intermediates and APIs. This will ensure a seamless integration into AFC’s network of production plants. AFC is witnessing robust customer demand for our core technologies combined with our development & manufacturing expertise. Customer response to this acquisition has been positive since it provides additional cGMP capacity in the US to support their current and future API needs.”

The Petersburg facility, now known as AFC-Virginia, includes four plants with multiple cGMP manufacturing lines totaling more than 80,000 gallons of cGMP capacity, the most recent of which was brought on-line in 2009. AFC-VA has a long history of producing Schedule II Controlled Substances. Capabilities also include High Potency manufacturing suites plus multiple 100 to 2000 gallon production bays.

This transaction is a continuation of AFC’s targeted acquisition strategy, first demonstrated in its successful integration of the AFC-Texas plant, which is now supporting numerous validated programs. Additionally, the AFC-California facility is undergoing a major expansion that is scheduled for completion in early 2017.

To view the full press release, click here. 

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!